chevron_leftBack
As of 13 July 2026, iNtRON Biotechnology, Inc. has a market cap of $78.87M USD, ranking #27242 globally and #1321 in South Korea.
It ranks #2443 in the Healthcare sector, and #882 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$78.87MUSD
118.24B KRW
Enterprise Value
$53.24MUSD
79.81B KRW
Revenue (TTM)
$3.83MUSD
5.74B KRW
EBITDA (TTM)
-$3.97MUSD
-5.96B KRW
Net Income (TTM)
-$5.98MUSD
-8.96B KRW
EBITDA Margin
-104%
Profit Margin
-156%
PS Ratio
20.6
PB Ratio
1.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73
Founded
1999
Website
intron.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.5% | -3.7% | -11% | -2% | 3.3% | -8.3% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
048530
(주)인트론바이오테크놀로지
ISIN: KR7048530000
Shares Out.:
Shares Outstanding:
30.17M1
Shares Float:
23.785M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3,610 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About iNtRON Biotechnology, Inc.
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.28B
12K%
13.91T KRW
|
-
|
|
KRX: 326030
|
$5.32B
7K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$5.03B
6K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.62B
6K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.51B
6K%
6.76T KRW
|
-
|
|
KRX: 128940
|
$4.09B
5K%
6.12T KRW
|
36.1
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
966K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
694K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
457K%
|
97.4
|
|
SIX: RO
|
$316.87B
402K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.92B
366K%
215.59B GBP
|
27.6
|
|
NYSE: MRK
|
$274.03B
347K%
|
15.1
|
chevron_leftBack